Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 23;16(9):1619.
doi: 10.3390/cancers16091619.

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Evangelia Bogatsa  1 , George Lazaridis  1 , Chrysoula Stivanaki  1 , Eleni Timotheadou  1
Affiliations
Review

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Evangelia Bogatsa et al. Cancers (Basel). .

Abstract

Non-small cell lung cancer, even when diagnosed in early stages, has been linked with poor survival rates and distant recurrence patterns. Novel therapeutic approaches harnessing the immune system have been implemented in early stages, following the designated steps of advanced NSCLC treatment strategies. Immune-checkpoint inhibitor (ICI) regimens as monotherapy, combinational, or alongside chemotherapy have been intensely investigated as adjuvant, neoadjuvant, and, more recently, perioperative therapeutic strategies, representing pivotal milestones in the evolution of early lung cancer management while holding great potential for the future. The subject of current ongoing research is optimizing treatment outcomes for patient subsets with different needs and identifying biomarkers that could be predictive of response while translating the trials' endpoints to survival rates. The aim of this review is to discuss all current treatment options with the pros and cons of each, persistent challenges, and future perspectives on immunotherapy as illuminating the path to a new era for resectable NSCLC.

Keywords: adjuvant; early; immune-checkpoint inhibitors; immunotherapy; neoadjuvant; non-small cell lung cancer; perioperative; resectable.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Milestones of adjuvant/neoadjuvant therapy in early NSCLC. Data from [3,5,9,10,11,12].
Figure 2
Figure 2
Major adjuvant/neoadjuvant immunotherapy trials per disease stage. Data from [9,10,12,28,29,42,43,44,45,46,47,48].
See this image and copyright information in PMC

References

    1. West H., Hu X., Zhang S., Song Y., Chirovsky D., Gao C., Lerner A., Jiang A., Signorovitch J., Samkari A. Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data. Clin. Lung Cancer. 2023;24:260–268. doi: 10.1016/j.cllc.2022.12.005. - DOI - PubMed
    1. John A.O., Ramnath N. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. Oncologist. 2023;28:752–764. doi: 10.1093/oncolo/oyad125. - DOI - PMC - PubMed
    1. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., Dunant A., Torri V., Rosell R., Seymour L., et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008;26:3552–3559. doi: 10.1200/JCO.2007.13.9030. - DOI - PubMed
    1. Song W.A., Zhou N.K., Wang W., Chu X.Y., Liang C.Y., Tian X.D., Guo J.T., Liu X., Liu Y., Dai W.M. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: An updated meta-analysis of 13 randomized control trials. J. Thorac. Oncol. 2010;5:510–516. doi: 10.1097/JTO.0b013e3181cd3345. - DOI - PubMed
    1. Lim E., Harris G., Patel A., Adachi I., Edmonds L., Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: Systematic review and indirect comparison meta-analysis of randomized trials. J. Thorac. Oncol. 2009;4:1380–1388. doi: 10.1097/JTO.0b013e3181b9ecca. - DOI - PubMed

LinkOut - more resources